The discovery of immune checkpoint pathways such as the CTLA-4 and PD-1 axes, and their subsequent blockade by inhibiting antibodies (including, but not restricted to, anti-CTLA-4, anti-PD-1 and anti-PD-L1) has revolutionized the field of immunotherapy for cancer (1, 2). This evidence concerns the gene CTLA4 and cancer.